Objective: To evaluate the diagnostic value of serum Golgi protein 73 (GP73) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: A computer-based systematic search of publically published literature of relevant studies in China and abroad was performed. The indexes for diagnostic accuracy were pooled, and the area under carve (AUC) of the summary receiver operating characteristic carve (SROC) and Q* index were calculated by using Meta-Disc1.4 software. The post-test probability was calculated, and Fagan’s nomograms were drawn to assess the application value of GP73 by using Stata 14.0 software. Results: A total of 14 studies were finally included, with a total sample size of 3 953 subjects. The pooled sensitivity and specificity of GP73 in diagnosis of HBV-related HCC were 0.70 (95% CI=0.68 0.73) and 0.75 (95% CI=0.73–0.77) respectively, and the pooled positive likelihood ratio and negative likelihood ratio were 3.37 (95% CI=2.75–4.13) and 0.36 (95% CI=0.29 0.45), respectively. The summary diagnostic odds ratio (DOR) was 9.67 (95% CI=6.72–13.91), and the AUC and Q* index were 0.826 and 0.759, respectively. For a pre-test probability of 50%, the post-test probabilities for positive and negative test of GP73 were 78% and 26%, respectively. Conclusion: GP73 has certain value in diagnosis of HBV-related HCC, but the value of its lone use for confirmation or exclusion of this disease is limited and other combined examinations are required.